Aprea Therapeutics, Inc. (APRE) |
| 0.943 0.002 (0.21%) 04-15 16:00 |
| Open: | 0.9074 |
| High: | 0.9687 |
| Low: | 0.8782 |
| Volume: | 384,904 |
| Market Cap: | 6(M) |
| PE Ratio: | -0.49 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 1.13 |
| Resistance 1: | 0.97 |
| Pivot price: | 0.76 |
| Support 1: | 0.77 |
| Support 2: | 0.65 |
| 52w High: | 2.22 |
| 52w Low: | 0.548 |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Financials
| EPS | -13210000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -63.484 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -79.00 |
| Return on Assets (ttm) | 205.7 |
| Return on Equity (ttm) | -41.5 |
Company news
Wed, 15 Apr 2026
APRE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Tue, 07 Apr 2026
Aprea Therapeutics, Inc. - Common Stock (NQ: APRE - FinancialContent
Thu, 02 Apr 2026
APRE SEC Filings - Aprea Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Wed, 01 Apr 2026
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement - The Globe and Mail
Wed, 01 Apr 2026
Aprea Therapeutics (NASDAQ: APRE) closes $30M oversubscribed funding - Stock Titan
Tue, 31 Mar 2026
Aprea Therapeutics Announces $30 Million Private Placement - The Globe and Mail
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
